* Spectrum Pharmaceuticals Inc SPPI.OQ SPPI.O is
expected
to show no change in quarterly revenue when it reports
results on August 11.
* Refinitiv's mean analyst estimate for Spectrum
Pharmaceuticals
Inc is for a loss of 16 cents per share. For the same quarter
last year, the company reported a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Spectrum
Pharmaceuticals Inc is $4, above its last closing price
of $1.10.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.20 -0.19 -0.08 Beat 58.3
Dec. 31 2022 -0.21 -0.26 Missed -21.5
Sep. 30 2021 -0.28 -0.28 -0.21 Beat 25
Jun. 30 2021 -0.25 -0.25 -0.32 Missed -25.5
Mar. -0.30 -0.31 -0.25 Beat 20.6
31 2021
Dec. 31 2020 -0.29 -0.29 Met 0
Sep. 30 2020 -0.35 -0.35 -0.37 Missed -5.7
Jun. 30 2020 -0.29 -0.32 -0.28 Beat 11.4
This summary was machine generated August 9 at 18:31 GMT. All
figures in US dollars unless otherwise stated